Plasma Cluster of Differentiation 147 and Cognitive Impairment After Acute Ischemic Stroke.

J Am Heart AssocSep 9, 2026 (epub)
Clinical ResearchNeurologyInternal Medicine (General)

Wenyu Zhao, Lulu Sun, Jiaxin Zan et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial investigated the relationship between plasma CD147 levels and poststroke cognitive impairment (PSCI) in 612 patients with acute ischemic stroke. The study found that elevated plasma CD147 levels were associated with higher odds of PSCI, with an odds ratio of 1.75 (95% CI, 1.21-2.51) after multivariate adjustment.

Key findings

  • 317 participants developed PSCI as defined by the Mini-Mental State Examination.
  • Elevated plasma CD147 levels were associated with an odds ratio of 1.75 for PSCI.
  • Adding plasma CD147 to conventional risk factors improved discriminatory power (C statistics, 0.695 vs 0.711).
  • Similar associations were observed using the Montreal Cognitive Assessment for PSCI.

Why it matters

Understanding the role of plasma CD147 in cognitive impairment after stroke could help identify patients at risk for PSCI, potentially guiding monitoring and intervention strategies in clinical practice.

Source

PubMed · PMID 42714478

Published in J Am Heart Assoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.